[CLAIMS]

[Claim 1]

An immunity enhancing agent, comprising an Allergin-1 antagonist as an active ingredient.

[Claim 2]

The agent according to claim 1, for use in the suppression of progress of, the suppression of recurrence of and/or the treatment of cancer.

[Claim 3]

Use of an Allergin-1 antagonist in the manufacture of an immunity enhancing agent for the treatment of cancer.

[Claim 4]

The agent according to claim 1, or the use according to claim 3, wherein the Allergin-1 antagonist suppresses immunosuppressive intracellular signalling of Allergin-1.

[Claim 5]

The agent according to claim 1 or claim 4, or the use according to claim 3 or claim 4, wherein the Allergin-1 antagonist is an anti-Allergin-1 antibody, an Allergin-1 binding protein or an Allergin-1-fusion protein.

[Claim 6]

The agent or the use according to claim 5, wherein the anti-Allergin-1 antibody is an anti-human Allergin-1 antibody.

[Claim 7]

The agent or the use according to claim 5 or claim 6, wherein the anti-Allergin-1 antibody is a monoclonal antibody.

[Claim 8]

The agent or the use according to claim 7, wherein the anti-Allergin-1 monoclonal antibody is of IgG_1 or IgG_4 isotype.

[Claim 9]

The agent or the use according to claim 7 or claim 8, wherein the anti-Allergin-1 monoclonal antibody is an antibody fragment selected from the group consisting of Fab, Fab', Fv, scFv and $(Fab')_2$ fragments.

[Claim 10]

The agent or the use according to any one of claims 7 to 9, wherein the anti-Allergin-1 monoclonal antibody is a humanized or human antibody.

[Claim 11]

The agent or the use according to claim 7, wherein the anti-Allergin-1 monoclonal antibody is a humanized or human anti-human Allergin-1 monoclonal IgG_1 or IgG_4 antibody.

[Claim 12]

The agent or the use according to claim 5 or claim 6, wherein the anti-Allergin-1 antibody is an Allergin-1 multispecific antibody recognizing two or more different epitopes present on one Allergin-1 molecule.

[Claim 13]

The agent or the use according to any one of claims 3 to 12, wherein the cancer is solid cancer or hematologic cancer.

[Claim 14]

The agent or the use according to claim 13, wherein the solid

cancer is one or more selected from malignant melanoma, non-small cell lung cancer, small cell lung cancer, head and neck cancer, renal cell cancer, clear cell renal cell cancer, breast cancer, ovarian cancer, ovarian clear cell adenocarcinoma, bone and soft tissue sarcoma, glioblastoma, gliosarcoma, nasopharyngeal cancer, uterine cancer, anal cancer, colorectal cancer, hepatocellular cancer, esophageal cancer, pancreatic cancer, stomach cancer, urothelial cancer, prostate cancer, fallopian tube cancer, primary peritoneal cancer, pleural mesothelioma and myeloproliferative syndrome.

[Claim 15]

The agent or the use according to claim 13, wherein the hematologic cancer is one or more selected from multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma, acute myeloid leukaemia and chronic myeloid leukaemia.

[Claim 16]

The agent or the use according to any one of claims 1 to 15, which is to be administered to a cancer patient with insufficient therapeutic efficacy by an anti-cancer drug.

[Claim 17]

The agent or the use according to claim 16, wherein the anti-cancer drug is a tumor immunotherapeutic agent.

[Claim 18]

The agent or the use according to claim 17, wherein the tumor immunotherapeutic agent is one or more selected from an anti-PD-1

antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, a PD-L1 fusion protein, a PD-L2 fusion protein, an anti-CTLA-4 antibody, an anti-LAG-3 antibody, an anti-Tim3 antibody, an anti-KIR antibody, an anti-BTLA antibody, an anti-TIGIT antibody, an anti-VISTA antibody, an anti-CD137 antibody, an anti-OX40 antibody, an anti-HVEM antibody, an anti-CD27 antibody, an anti-GITR antibody, an anti-CD28 antibody, an anti-CCR4 antibody and an anti-CD4 antibody.

[Claim 19]

The agent or the use according to claim 18, wherein the anti-PD-1 antibody is Nivolumab, REGN-2810, Pembrolizumab, PDR-001, BGB-A317, STI-A1110 or AMP-514.

[Claim 20]

The agent or the use according to claim 18, wherein the anti-PD-L1 antibody is Atezolizumab, Avelumab, Durvalumab or BMS-936559.

[Claim 21]

The agent or the use according to claim 18, wherein the anti-CTLA-4 antibody is Ipilimumab or Tremelimumab.

[Claim 22]

The agent or the use according to claim 18, wherein the PD-L2 fusion protein is AMP-224.

[Claim 23]

The agent or the use according to any one of claims 1 to 22, wherein one or more anti-cancer drugs are to be further administered.

[Claim 24]

The agent or the use according to claim 23, wherein the Allergin-1 antagonist and the anti-cancer drug in different preparations are to be administered.

[Claim 25]

The agent or the use according to claim 23, wherein the Allergin-1 antagonist and the anti-cancer drug in one preparation is to be administered.

[Claim 26]

The agent or the use according to any one of claims 23 to 25, wherein the anti-cancer drug is a tumor immunotherapeutic agent.

[Claim 27]

The agent or the use according to claim 26, wherein the tumor immunotherapeutic agent is one or more selected from an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, a PD-L1 fusion protein, a PD-L2 fusion protein, an anti-CTLA-4 antibody, an anti-LAG-3 antibody, an anti-Tim3 antibody, an anti-KIR antibody, an anti-BTLA antibody, an anti-TIGIT antibody, an anti-VISTA antibody, an anti-CD137 antibody, an anti-OX40 antibody, an anti-HVEM antibody, an anti-CD27 antibody, an anti-GITR antibody, an anti-CD28 antibody, an anti-CCR4 antibody and an anti-CD4 antibody.

[Claim 28]

The agent or the use according to claim 27, wherein the anti-PD-1 antibody is Nivolumab, REGN-2810, Pembrolizumab, PDR-001, BGB-A317, STI-A1110 or AMP-514.

[Claim 29]

The agent or the use according to claim 27, wherein the anti-PD-L1 antibody is Atezolizumab, Avelumab or Durvalumab.

[Claim 30]

The agent or the use according to claim 27, wherein the anti-CTLA-4 antibody is Tremelimumab.

[Claim 31]

The agent or the use according to claim 27, wherein the PD-L2 fusion protein is AMP-224.

[Claim 32]

An Allergin-1 antagonist for use in enhancing the immunity against cancer in a cancer patient.